Cancer and neoplasms
Study finds increased MDS/leukemia risks for survivors of common lymphoid neoplasms
Aug
Survivors of common lymphoid neoplasms (LNs) have increased risks for therapy-related myelodysplastic syndrome/acute myeloid leukemia (tMDS/AML), although risks have been lower in more recent years, according to a study published in the July issue of eClinicalMedicine.
Lindsay M. Morton, Ph.D., from the National Cancer Institute in Bethesda, Maryland, and colleagues identified 1,496 tMDS/AML cases among 186,503 adults who were treated with initial chemotherapy/immunotherapy for first primary LN and survived one year or longer.
The researchers found that the highest risks for tMDS/AML occurred after precursor leukemia/lymphoma (standardized incidence ratio [SIR], 39; excess absolute risks [EAR], 30 per 10,000 person-years), Burkitt leukemia/lymphoma (SIR, 20; EAR, 24), peripheral T-cell lymphoma (SIR, 12; EAR, 23), chronic lymphocytic leukemia/small lymphocytic lymphoma (SIR, 9.0; EAR, 27), and mantle cell lymphoma (SIR, 8.5; EAR, 25).
After all other LN subtypes except hairy cell leukemia and mycosis fungoides/Sézary syndrome, elevated risks were also observed (SIRs, 4.2 to 6.9; EARs, 4.9 to 15). For patients treated more recently, tMDS/AML risks were significantly higher after chronic lymphocytic leukemia/small lymphocytic lymphoma (SIR2000-2005, 4.8; SIR2012-2017, 10), significantly lower after Hodgkin (SIR2000-2005, 15; SIR2012-2017, 6.3) and marginal zone (SIR2000-2005, 7.5; SIR2012-2017, 2.3) lymphomas, and nonsignificantly lower after mantle cell lymphoma, lymphoplasmacytic lymphoma/Waldenström macroglobulinemia, and plasma cell neoplasms. Trends for EAR and cumulative incidence were generally similar to those of SIR. Median survival was 8.0 months after tMDS/AML.
“Population-based data show that patients treated with initial chemo/immunotherapy for most lymphoid neoplasms may face increased tMDS/AML risks, but that tMDS/AML risks have evolved consistent with changes in treatment practices for certain subtypes,” the authors write.
More information:
Lindsay M. Morton et al, Trends in risk for therapy-related myelodysplastic syndrome/acute myeloid leukemia after initial chemo/immunotherapy for common and rare lymphoid neoplasms, 2000–2018, eClinicalMedicine (2023). DOI: 10.1016/j.eclinm.2023.102060
Copyright © 2023 HealthDay. All rights reserved.
Citation:
Study finds increased MDS/leukemia risks for survivors of common lymphoid neoplasms (2023, August 17)
retrieved 17 August 2023
from https://medicalxpress.com/news/2023-08-mdsleukemia-survivors-common-lymphoid-neoplasms.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
